180 related articles for article (PubMed ID: 37576886)
1. Effects of ranitidine and nizatidine on the risk of gastrointestinal cancer.
Kang H; Nam CM; Choi DW; Park S
Front Oncol; 2023; 13():1182174. PubMed ID: 37576886
[TBL] [Abstract][Full Text] [Related]
2. Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018.
Iwagami M; Kumazawa R; Miyamoto Y; Ito Y; Ishimaru M; Morita K; Hamada S; Tamiya N; Yasunaga H
Drug Saf; 2021 Mar; 44(3):361-371. PubMed ID: 33247391
[TBL] [Abstract][Full Text] [Related]
3. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Haag S; Holtmann G
Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
[TBL] [Abstract][Full Text] [Related]
4. 300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer. A multicentre trial in Europe.
Simon B; Cremer M; Dammann HG; Hentschel E; Keohane PP; Mulder H; Müller P; Sarles H
Scand J Gastroenterol Suppl; 1987; 136():61-70. PubMed ID: 2892257
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer--an 8-week randomized, double-blind multicentre study.
Di Mario F; Battaglia G; Naccarato R; D'Angelo A; Saggioro A; Da Broi GL; Vezzadini P; Bianchi Porro G
Hepatogastroenterology; 1990 Dec; 37 Suppl 2():62-5. PubMed ID: 1982108
[TBL] [Abstract][Full Text] [Related]
6. Effect of nizatidine versus ranitidine on gastric intraluminal prostaglandin release in duodenal ulcer patients.
Silecchia G; Spaziani E; Guarino E; Neri T; Grasso E; Mariani P; Materia A; Genco A; Basso N
Scand J Gastroenterol Suppl; 1994; 206():8-13. PubMed ID: 7863255
[TBL] [Abstract][Full Text] [Related]
7. Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease.
Thomson AB; Mahachai V; Bailey RJ; Kirdeikis P; Zuk L; Marriage B; Simpson I; Jamali F
J Gastroenterol Hepatol; 1996 Dec; 11(12):1171-6. PubMed ID: 9034938
[TBL] [Abstract][Full Text] [Related]
8. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial.
Kuipers EJ; Hazenberg HJ; Quik RF; Hazenberg BP; de Zwart PA
Neth J Med; 1990 Aug; 37(1-2):58-62. PubMed ID: 1977089
[TBL] [Abstract][Full Text] [Related]
9. Peptic ulcer in the elderly--a double-blind, short-term study comparing nizatidine 300 mg with ranitidine 300 mg. GISU (Interdisciplinary Ulcer Study Group).
Battaglia G; Di Mario F; Vigneri S; Dal Santo P; Pilotto A; Mazzacca G
Aliment Pharmacol Ther; 1993 Dec; 7(6):643-8. PubMed ID: 8161671
[TBL] [Abstract][Full Text] [Related]
10. Nizatidine versus ranitidine in gastric ulcer disease. A European multicentre trial.
Naccaratto R; Cremer M; Dammann HG; Keohane PP; Mulder H; Sarles H; Simon B
Scand J Gastroenterol Suppl; 1987; 136():71-8. PubMed ID: 2892258
[TBL] [Abstract][Full Text] [Related]
11. Ranitidine Use and Incident Cancer in a Multinational Cohort.
You SC; Seo SI; Falconer T; Yanover C; Duarte-Salles T; Seager S; Posada JD; Shah NH; Nguyen PA; Kim Y; Hsu JC; Van Zandt M; Hsu MH; Lee HL; Ko H; Shin WG; Pratt N; Park RW; Reich CG; Suchard MA; Hripcsak G; Park CH; Prieto-Alhambra D
JAMA Netw Open; 2023 Sep; 6(9):e2333495. PubMed ID: 37725377
[TBL] [Abstract][Full Text] [Related]
12. Nizatidine versus ranitidine in the prevention of duodenal ulcer relapse. Six-month interim results of a European multicentre study.
Hentschel E; Schütze K; Reichel W; Kerstan E; Kratochvil P; Brandstätter G; Judmaier G; Keohane PP
Scand J Gastroenterol Suppl; 1987; 136():84-8. PubMed ID: 2892260
[TBL] [Abstract][Full Text] [Related]
13. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine.
Fullarton GM; Macdonald AM; McColl KE
Aliment Pharmacol Ther; 1991 Aug; 5(4):391-8. PubMed ID: 1685675
[TBL] [Abstract][Full Text] [Related]
14. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
15. [Inhibition of 24-hour acidity by nizatidine].
Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
[TBL] [Abstract][Full Text] [Related]
16. [Effects of various histamine H2-receptor antagonists on gastrointestinal motility and gastric emptying].
Ohira Y; Hanyu N; Aoki T; Hashimoto Y; Iikura M; Fukuda S
J Smooth Muscle Res; 1993 Aug; 29(4):131-42. PubMed ID: 7907895
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of oral nizatidine and ranitidine on gastric volume and pH in patients undergoing gynaecological laparoscopy.
Popat MT; Dyar OJ; Blogg CE
Anaesthesia; 1991 Oct; 46(10):816-9. PubMed ID: 1683179
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of ranitidine and nizatidine in very elderly patients.
Sasaki M; Sudoh T; Fujimura A
Am J Ther; 2005; 12(3):223-5. PubMed ID: 15891265
[TBL] [Abstract][Full Text] [Related]
19. Nizatidine in the short-term treatment of duodenal ulcer--an Italian Multicenter Study.
Bovero E; Poletti M; Boero A; Mura BC; Camarri E; Corradini P; Corsini G; Federici G; Curzio M; Gianquinto G
Hepatogastroenterology; 1987 Dec; 34(6):269-71. PubMed ID: 2892768
[TBL] [Abstract][Full Text] [Related]
20. Spectrophotometric determination of nizatidine and ranitidine through charge transfer complex formation.
Walash M; Sharaf-El Din M; Metwalli ME; RedaShabana M
Arch Pharm Res; 2004 Jul; 27(7):720-6. PubMed ID: 15356997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
